PAVANELLO, CHIARA
 Distribuzione geografica
Continente #
EU - Europa 6.891
AS - Asia 5.870
NA - Nord America 5.702
SA - Sud America 646
AF - Africa 194
OC - Oceania 102
Continente sconosciuto - Info sul continente non disponibili 8
Totale 19.413
Nazione #
US - Stati Uniti d'America 5.348
IT - Italia 2.032
CN - Cina 1.803
SG - Singapore 1.594
GB - Regno Unito 1.491
DE - Germania 989
HK - Hong Kong 501
BR - Brasile 427
FR - Francia 372
VN - Vietnam 363
RU - Federazione Russa 327
IN - India 301
SE - Svezia 279
JP - Giappone 267
BD - Bangladesh 229
NL - Olanda 213
CA - Canada 200
ES - Italia 197
IE - Irlanda 182
TR - Turchia 151
FI - Finlandia 142
ID - Indonesia 127
DK - Danimarca 105
MX - Messico 103
AU - Australia 91
TW - Taiwan 91
KR - Corea 90
PL - Polonia 87
AT - Austria 81
AR - Argentina 61
CH - Svizzera 54
UA - Ucraina 52
CO - Colombia 49
CI - Costa d'Avorio 48
ZA - Sudafrica 47
BE - Belgio 46
SA - Arabia Saudita 46
CL - Cile 40
GR - Grecia 37
IR - Iran 35
TH - Thailandia 35
RO - Romania 33
MY - Malesia 32
JO - Giordania 31
HU - Ungheria 30
IQ - Iraq 29
PT - Portogallo 26
PK - Pakistan 24
CZ - Repubblica Ceca 23
EG - Egitto 22
PH - Filippine 21
VE - Venezuela 21
AE - Emirati Arabi Uniti 18
TN - Tunisia 18
RS - Serbia 16
IL - Israele 15
EC - Ecuador 14
CR - Costa Rica 13
MA - Marocco 13
PE - Perù 13
UZ - Uzbekistan 13
HN - Honduras 11
QA - Qatar 11
HR - Croazia 10
NZ - Nuova Zelanda 10
BG - Bulgaria 8
BO - Bolivia 8
ET - Etiopia 8
NO - Norvegia 8
SC - Seychelles 8
SI - Slovenia 8
BH - Bahrain 7
LV - Lettonia 7
PY - Paraguay 7
SK - Slovacchia (Repubblica Slovacca) 7
KE - Kenya 6
LT - Lituania 6
UY - Uruguay 6
GH - Ghana 5
JM - Giamaica 5
MT - Malta 5
PR - Porto Rico 5
SV - El Salvador 5
AZ - Azerbaigian 4
DZ - Algeria 4
LB - Libano 4
LK - Sri Lanka 4
PS - Palestinian Territory 4
BB - Barbados 3
BY - Bielorussia 3
EE - Estonia 3
EU - Europa 3
IS - Islanda 3
KW - Kuwait 3
LU - Lussemburgo 3
NP - Nepal 3
OM - Oman 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
KZ - Kazakistan 2
Totale 19.373
Città #
Southend 1.081
Singapore 959
Ashburn 584
Milan 577
Hong Kong 414
San Jose 335
Frankfurt am Main 324
Dallas 319
Hanover 295
Beijing 245
Chandler 242
Fairfield 224
Redwood City 191
Council Bluffs 181
Wilmington 169
Dublin 157
Seattle 155
Houston 148
New York 148
Los Angeles 147
Hefei 146
Rome 128
Woodbridge 124
Ho Chi Minh City 111
Ann Arbor 109
Princeton 101
Cambridge 98
Santa Clara 96
Istanbul 90
Helsinki 88
Bengaluru 87
Shanghai 86
Jakarta 84
Nanjing 84
Dearborn 82
Guangzhou 82
Lauterbourg 82
Hanoi 81
Tokyo 77
Buffalo 64
Toronto 63
Taipei 61
Turin 60
Grafing 57
Munich 55
São Paulo 54
Abidjan 48
Moscow 47
Fuzhou 45
London 39
Chicago 37
Jinan 36
Paris 36
Des Moines 35
Vienna 35
Genoa 34
Boardman 33
Naples 32
Palermo 32
Shenyang 32
Madrid 31
Phoenix 31
Tianjin 31
Berlin 30
San Diego 30
Shenzhen 30
The Dalles 30
Amman 29
Seoul 29
Warsaw 29
Barcelona 28
Cangzhou 27
Hangzhou 27
Montreal 26
Washington 26
Buenos Aires 24
Changsha 24
Nuremberg 24
Zhengzhou 24
Amsterdam 23
Athens 23
Delhi 22
Mumbai 22
Orem 22
Philadelphia 22
Bangkok 21
Bogotá 20
Bologna 20
Da Nang 19
Padova 19
Sydney 19
Ankara 18
Columbus 18
Ningbo 18
San Francisco 18
Santiago 18
Cape Town 17
Fremont 17
Haiphong 17
Lappeenranta 17
Totale 10.606
Nome #
Effect of soy on metabolic syndrome and cardiovascular risk factors : a randomized controlled trial 1.775
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 941
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study 915
Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study 811
LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters 593
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) 525
A proteomic approach to identify novel disease biomarkers in LCAT deficiency 445
Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients 438
The PPAR pan-agonist tetradecylthioacetic acid promotes redistribution of plasma cholesterol towards large HDL 423
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study 416
Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract : results from a randomized, double-blind, placebo-controlled study 383
Influence of body variables in the development of metabolic syndrome : A long term follow-up study 355
GENETIC LCAT DEFICIENCY AND ATHEROSCLEROSIS: STUDIES ON ENDOTHELIAL CELLS AND MONOCYTES 305
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET) 289
Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting : the PROSISA Study 287
Valutazione dei benefici salutistici dell'assunzione dI proteine della soia in pazienti con moderata sindrome metabolica 285
Systematic Lab Knowledge Integration for Management of Lipid Excess in High-Risk Patients : Rationale and Design of the SKIM LEAN Project 262
Evaluation of the health benefits of soy protein consumption in patients carrying the metabolic syndrome 256
Nutraceutical approach to moderate cardiometabolic risk : results of a randomized, double-blind and crossover study with Armolipid Plus 248
Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red Yeast Rice Extract) (Randomized, Double-Blind, Placebo-Controlled Study) 242
Effects of a lupin protein concentrate on lipids, blood pressure and insulin resistance in moderately dyslipidaemic patients : a randomised controlled trial 235
The HDL mimetic CER-001 remodels plasma lipoproteins and reduces kidney lipid deposits in inherited lecithin:cholesterol acyltransferase deficiency 233
Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation 232
Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes : evidence in NAFLD patients and cell cultures 230
Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels 227
Plasma and cerebrospinal fluid cholesterol esterification is hampered in Alzheimer's disease 221
Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos) 219
Progression of chronic kidney disease in Familial LCAT Deficiency: a follow-up of the Italian cohort 212
Dysfunctional HDL as a therapeutic target for atherosclerosis prevention 208
null 200
Metformin: From diabetes to cancer to prolongation of life 194
Considering gender in prescribing statins : what do physicians need to know? 181
Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia 180
Triglyceride-glucose index: carotid intima-media thickness and cardiovascular risk in a European population 178
Case report: Unusual and extremely severe lipoprotein X-mediated hypercholesterolemia in extrahepatic pediatric cholestasis 176
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH) : a cross-national retrospective survey 173
Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production 166
Novel therapeutic strategies for the homozygous familial hypercholesterolemia 166
CA-IMT and QT parameters in dyslipidemic patients in primary prevention at different ESC/EAS cardiovascular risk levels 165
HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD) 165
Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open label interventional study 163
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia 162
Autosomal recessive hypercholesterolemia : long-term cardiovascular outcomes 160
Apolipoprotein E isoforms differentially affect LCAT-dependent cholesterol esterification 154
Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation 152
Cardiovascular determinants of QT interval duration in dysplipidemic patients in primary prevention in two genders 151
Genetic and phenotypic characterization of LDL-receptor in patients with a clinical diagnosis of familial hypercholesterolemia: two novel mutations 147
Plasma FA composition in familial LCAT deficiency indicates SOAT2-derived cholesteryl ester formation in humans 147
Sex-related differences in response to lomitapide in HoFH: A subanalysis of the Pan-European Lomitapide retrospective observational study 146
Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency 146
Abnormal Lipoproteins Trigger Oxidative Stress-Mediated Apoptosis of Renal Cells in LCAT Deficiency 146
Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group 145
Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention 145
Exploiting routine laboratory test to identify primary severe hypertriglyceridaemic patients in a large Italian hospital 144
Appropriateness of statin prescription in the elderly 142
HDL-replacement therapy: From traditional to emerging clinical applications 140
Nutraceutical approaches to metabolic syndrome 140
Soya-enriched mixed diet significantly improves cardiovascular and metabolic risk factors : A randomized controlled trial 138
The relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype with preclinical atherosclerosis 136
Genetic characterization of LDL-receptor in patients with a clinical diagnosis of familial hypercholesterolemia: two novel mutations 136
Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features 136
HDL and chronic kidney disease 136
Inhibition of ATP citrate lyase does not affect muscle mitochondrial activity in apoE-/- mice 129
Flipped C-Terminal Ends of apoA1 Promote ABCA1-Dependent Cholesterol Efflux by Small HDLs 128
Microsomal transfer protein (MTP) inhibition : a novel approach to the treatment of homozygous hypercholesterolemia 127
Plasma lipoproteins of patients with genetic LAL deficiency are enriched in cholesteryl esters: Relevance of cholesterol esterification by LCAT 127
Spring Meeting of the Young Researchers of SID, SIIA, SIMI, SIPREC, SISA 126
Evaluation of high-density lipoprotein-bound long non-coding RNAs in subjects with familial hypercholesterolaemia 125
Genetic, biochemical, and clinical features of LCAT deficiency: update for 2020 125
Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study 124
Generation and validation of a classification model to diagnose familial hypercholesterolaemia in adults 122
Two novel variants in the lecithin:cholesterol acyltransferase gene resulted in classic LCAT deficiency 116
Lipoprotein (a) : concentration, isoforms, polymorphisms and association with preclinical atherosclerosis 115
High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis 115
Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning 113
Gender-specific comparison of six QT correction formulae in dyslipidemic patients in primary prevention 112
Emerging Therapies for Familial Lecithin-Cholesterol Acyltransferase Deficiency: A Role for Plasma Exchange 110
Three new italian cases of LCAT deficiency 107
Familial LCAT deficiency and cardiovascular disease: the game is not over. A case of dramatic multivessel atherosclerosis 106
Contemporary Management of Familial and Multifactorial Chylomicronemia Syndromes in Italy: Insights From the National Lipigen Registry 102
Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia : Results of a Real-World Clinical Experience in Italy 99
Clinical implementation of bempedoic acid in blood lipid management: real-world data from an italian lipid clinic 96
Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry 96
Response to treatment and occurrence of cardiovascular (CV) complications in patients with autosomal recessive hypercholesterolemia (ARH): A retrospective analysis 75
Spring Meeting of the Young Researchers of SID, SIGG, SIIA, SIMI, SIPREC, SISA 73
Lipidome of high-density lipoprotein is strongly perturbed in hyperalphalipoproteinemia resulting from a rare mutation in endothelial lipase 63
LDL-C target achievement after adding evinacumab in 2 patients with autosomal recessive hypercholesterolemia 37
Bempedoic acid does not affect skeletal muscle mitochondrial activity in apoE-/- mice 29
Cerebrospinal fluid CEFA composition is enriched in saturated fatty acids and it is altered in Alzheimer's Disease 25
Impact of bempedoic acid on skeletal muscle mitochondrial activity in ApoE-/- mice – a preliminary analysis 10
Activation of naturally occurring LCAT mutants by a novel activator compound 5
Activation of Naturally Occurring Lecithin:Cholesterol Acyltransferase Mutants by a Novel Activator Compound 4
Totale 20.108
Categoria #
all - tutte 50.870
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.870


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021253 0 0 0 0 0 0 0 0 0 0 138 115
2021/20221.636 108 112 121 157 130 170 116 110 161 145 114 192
2022/20231.896 126 121 107 103 170 232 143 177 234 126 209 148
2023/20241.897 168 188 195 246 312 95 90 115 66 93 163 166
2024/20253.028 128 273 110 259 239 156 156 297 230 318 307 555
2025/20266.626 604 475 757 566 623 395 866 304 693 549 794 0
Totale 20.108